List view / Grid view
1 March 2017 | By Dorothea Wenzel, Senior VP Global Business Franchise Fertility, Merck
We caught up with Merck's Dorothea Wenzel to hear all about the latest in fertility treatments, training and technologies and to find out the truth about infertility...
1 March 2017 | By Niamh Louise Marriott, Digital Editor
This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).
A defining characteristic of inhaled drug delivery is variability in the dose received by the patient, as a result of physiology, for example, or the technique applied during use. This variability directly affects clinical outcomes so reducing it to a minimum is an important goal for the industry...
For the pharmaceutical scientist, the journey of an active molecule from the end of its synthetic pathway and crystallisation to its ultimate site of action is a fascinating one, and one that is necessary to understand...
Commercial biomanufacturing dates to thousands of years and the first biological engine, the yeast, continues to be beneficial...
Near-infrared spectroscopy (NIRS) is used by the pharmaceutical industry for a wide variety of applications, including the identification of drug substances, products and raw materials; tablet assays; uniformity of content; water content; solid state form; and process analytical technologies...
Near-infrared spectroscopy (NIRS) is a rapid and non-destructive analytical technique that is important in analysing or profiling both solid and liquid dosage forms, as well as biotechnological products...
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
Pharmaceutical QbD: Omnipresence in the product development lifecycle; Expert View with Kaiser Optical Systems Inc.; and Reinventing commercial biomanufacturing...
In this NIR In-Depth Focus: Monitoring and controlling drug products and manufacturing processes with NIRS; Development of a NIRS method for quantification of a minor polymorphic form; and an Expert View with Metrohm Process Analytics...
Understanding the effect of API changes in pharmaceutical processing; Improving the consistency of MDI drug delivery; and Expert Views with DDF Summit and Eurofins Lancaster Laboratories...
In this Guide to QA/QC Instrumentation, we consider the Sievers M9 series of TOC Analyzers from GE Analytical Instruments, and METTLER TOLEDO’s UV7 Spectrophotometer...
22 February 2017 | By Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group
Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally...
The British Pharmacopoeia (BP) is a collection of authoritative and publicly available quality standards for medicines, supported by guidance and additional value-adding information. First published in 1864, the BP has an illustrious history that has been built on quality and continually responds to the needs of stakeholders and users.
The first part of an in-depth article on Quality by Design (QbD), published in European Pharmaceutical Review in December 2016, focused on designing quality in to a pharmaceutical drug product by considering dosage form design, and understanding the importance of active pharmaceutical ingredients’ (APIs’) and excipients’ properties.
